Cargando…

Association between serum biomarkers CEA and LDH and response in advanced non‐small cell lung cancer patients treated with platinum‐based chemotherapy

BACKGROUND: In addition to radiological evaluation, biomarkers may be useful in providing early information on the response to treatment, and supporting clinical decision‐making. The objective of this study was to investigate carcinoembryonic antigen (CEA) and lactate dehydrogenase (LDH) as biomarke...

Descripción completa

Detalles Bibliográficos
Autores principales: de Jong, Corine, Deneer, Vera H.M., Kelder, Johannes C., Ruven, Henk, Egberts, Toine C.G., Herder, Gerarda J.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327701/
https://www.ncbi.nlm.nih.gov/pubmed/32383328
http://dx.doi.org/10.1111/1759-7714.13449
_version_ 1783552598263988224
author de Jong, Corine
Deneer, Vera H.M.
Kelder, Johannes C.
Ruven, Henk
Egberts, Toine C.G.
Herder, Gerarda J.M.
author_facet de Jong, Corine
Deneer, Vera H.M.
Kelder, Johannes C.
Ruven, Henk
Egberts, Toine C.G.
Herder, Gerarda J.M.
author_sort de Jong, Corine
collection PubMed
description BACKGROUND: In addition to radiological evaluation, biomarkers may be useful in providing early information on the response to treatment, and supporting clinical decision‐making. The objective of this study was to investigate carcinoembryonic antigen (CEA) and lactate dehydrogenase (LDH) as biomarkers for early assessment of response in patients with advanced non‐small cell lung cancer (NSCLC) treated with platinum‐based chemotherapy. METHODS: A retrospective follow‐up study was conducted from 2012 to 2017 among 593 consecutive patients with advanced NSCLC treated with first‐line platinum‐based chemotherapy in a large teaching hospital in the Netherlands. Pretreatment biomarker levels and changes from pretreatment levels were studied for association with radiologic response (partial response [PR] or complete response [CR], according to RECIST 1.1) using multivariate logistic regression, and with overall survival using COX proportional hazard modeling. Patient and disease characteristics such as age and disease stage were taken into account as potential confounding factors. RESULTS: Decreases in CEA and LDH (≥ 20%), particularly early in treatment, were significantly associated with better radiological response. Increases in these biomarkers (≥ 20%) and high pretreatment LDH levels (≥ 247 U/L) were significantly associated with lower overall survival. CONCLUSIONS: Our results support determination of CEA and LDH levels for earlier assessment of response to platinum‐based chemotherapy in patients with advanced NSCLC. Hence, routine determination and evaluation of CEA and LDH levels, prior to each cycle of platinum‐based chemotherapy in advanced NSCLC, should be considered as part of daily clinical practice. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: Serum biomarkers in monitoring of treatment in advanced NSCLC would be useful. CEA and LDH decrease (≥ 20%) is favorable for achieving radiological response. High LDH levels and CEA/LDH increase (≥ 20%) is associated with reduced survival. WHAT THIS STUDY ADDS: Monitoring of CEA seems to be particularly relevant in early stage of treatment. CEA and LDH determination should be considered as part of daily clinical practice.
format Online
Article
Text
id pubmed-7327701
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-73277012020-07-02 Association between serum biomarkers CEA and LDH and response in advanced non‐small cell lung cancer patients treated with platinum‐based chemotherapy de Jong, Corine Deneer, Vera H.M. Kelder, Johannes C. Ruven, Henk Egberts, Toine C.G. Herder, Gerarda J.M. Thorac Cancer Original Articles BACKGROUND: In addition to radiological evaluation, biomarkers may be useful in providing early information on the response to treatment, and supporting clinical decision‐making. The objective of this study was to investigate carcinoembryonic antigen (CEA) and lactate dehydrogenase (LDH) as biomarkers for early assessment of response in patients with advanced non‐small cell lung cancer (NSCLC) treated with platinum‐based chemotherapy. METHODS: A retrospective follow‐up study was conducted from 2012 to 2017 among 593 consecutive patients with advanced NSCLC treated with first‐line platinum‐based chemotherapy in a large teaching hospital in the Netherlands. Pretreatment biomarker levels and changes from pretreatment levels were studied for association with radiologic response (partial response [PR] or complete response [CR], according to RECIST 1.1) using multivariate logistic regression, and with overall survival using COX proportional hazard modeling. Patient and disease characteristics such as age and disease stage were taken into account as potential confounding factors. RESULTS: Decreases in CEA and LDH (≥ 20%), particularly early in treatment, were significantly associated with better radiological response. Increases in these biomarkers (≥ 20%) and high pretreatment LDH levels (≥ 247 U/L) were significantly associated with lower overall survival. CONCLUSIONS: Our results support determination of CEA and LDH levels for earlier assessment of response to platinum‐based chemotherapy in patients with advanced NSCLC. Hence, routine determination and evaluation of CEA and LDH levels, prior to each cycle of platinum‐based chemotherapy in advanced NSCLC, should be considered as part of daily clinical practice. KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: Serum biomarkers in monitoring of treatment in advanced NSCLC would be useful. CEA and LDH decrease (≥ 20%) is favorable for achieving radiological response. High LDH levels and CEA/LDH increase (≥ 20%) is associated with reduced survival. WHAT THIS STUDY ADDS: Monitoring of CEA seems to be particularly relevant in early stage of treatment. CEA and LDH determination should be considered as part of daily clinical practice. John Wiley & Sons Australia, Ltd 2020-05-07 2020-07 /pmc/articles/PMC7327701/ /pubmed/32383328 http://dx.doi.org/10.1111/1759-7714.13449 Text en © 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
de Jong, Corine
Deneer, Vera H.M.
Kelder, Johannes C.
Ruven, Henk
Egberts, Toine C.G.
Herder, Gerarda J.M.
Association between serum biomarkers CEA and LDH and response in advanced non‐small cell lung cancer patients treated with platinum‐based chemotherapy
title Association between serum biomarkers CEA and LDH and response in advanced non‐small cell lung cancer patients treated with platinum‐based chemotherapy
title_full Association between serum biomarkers CEA and LDH and response in advanced non‐small cell lung cancer patients treated with platinum‐based chemotherapy
title_fullStr Association between serum biomarkers CEA and LDH and response in advanced non‐small cell lung cancer patients treated with platinum‐based chemotherapy
title_full_unstemmed Association between serum biomarkers CEA and LDH and response in advanced non‐small cell lung cancer patients treated with platinum‐based chemotherapy
title_short Association between serum biomarkers CEA and LDH and response in advanced non‐small cell lung cancer patients treated with platinum‐based chemotherapy
title_sort association between serum biomarkers cea and ldh and response in advanced non‐small cell lung cancer patients treated with platinum‐based chemotherapy
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327701/
https://www.ncbi.nlm.nih.gov/pubmed/32383328
http://dx.doi.org/10.1111/1759-7714.13449
work_keys_str_mv AT dejongcorine associationbetweenserumbiomarkersceaandldhandresponseinadvancednonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT deneerverahm associationbetweenserumbiomarkersceaandldhandresponseinadvancednonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT kelderjohannesc associationbetweenserumbiomarkersceaandldhandresponseinadvancednonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT ruvenhenk associationbetweenserumbiomarkersceaandldhandresponseinadvancednonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT egbertstoinecg associationbetweenserumbiomarkersceaandldhandresponseinadvancednonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy
AT herdergerardajm associationbetweenserumbiomarkersceaandldhandresponseinadvancednonsmallcelllungcancerpatientstreatedwithplatinumbasedchemotherapy